|
Faam et al. (30)
|
Tehran (TLGS, phase 3), local study |
Healthy adults |
Random sampling |
2005 - 2008 |
2013 |
20 - 70 |
T: 40.7 ± 13.9 |
Both |
U |
T: 4,665; M: 1,976; F: 2,689 |
JIS |
Participants who had diabetes mellitus (n = 390) or body mass index (BMI) less than 18 kg/m (n = 152) were exclude.Waist circumference cut-off points were not mentioned |
T: 31.5 (30.1 - 32.8) |
|
Ziaee et al. (31)
|
Mindoodar district of Qazvin, local study |
Healthy adults |
Multistage random cluster sampling |
2010 - 2011 |
2013 |
20 - 78 |
T: 40.08 ± 10.33; M: 42.31 ± 10.56; F: 38.02 ± 9.69 |
Both |
R |
T: 1,107; M: 529; F: 578 |
JIS |
Waist circumference cut-off points were ≥ 94 cm in men or ≥ 80 cm in women |
T: 39.3 (36.4 - 42.2) |
|
Movahed et al. (32)
|
Bushehr Port, (Iranian Multicentral Osteoporosis Study), local study |
Postmenopausal women |
Randomcluster sampling |
2006 |
2012 |
50 - 83 |
F: 58.78 ± 7.8 |
F |
U |
T: 382 |
ATP III |
|
T: 68.32 (63.3 - 72.9) |
|
Yousefzadeh et al. (33)
|
Kerman,local study |
Healthy adults |
Random sampling |
|
2012 |
15 - 75 |
T: 46.52 ± 14.76 |
Both |
U |
T: 200; M: 81; F: 119 |
Modified ATP III |
|
T: 60 (52.8 - 66.8) |
|
Azimi-Nezhad et al. (34)
|
Greater Khorasan province, (National Survey on Non-communicable Disease), local study |
Healthy adults |
Multistage random sampling |
2003 |
2012 |
35 - 55 |
|
Both |
|
T: 1,194; M: 58; F: 605 |
Modified ATP III |
|
T: 42.66 (39.8 - 45.4); M: 30.1 (26.3 - 33.9); F: 55.0 (50.9 - 59.0) |
|
Hadaegh et al. (35)
|
Tehran (TLGS, phase 1), local study |
Subjects free of CVD |
Random sampling |
1999 - 2001 |
2012 |
40 ≤ |
T:54 ± 9.8; M: 55.3 ± 10.5; F: 53.0 ± 9.3 |
Both |
U |
T: 4,248; M:1,856 F:2,392 |
JIS |
Waist circumference cut-off point was ≥ 94.5 cm for both Iranian men and women |
T: 51.6 (50 - 53.1); M: 45.7 (43.4 - 47.9); F: 56.2 (54.1 - 58.1) |
|
Talaei et al. (36)
|
Isfahan, Arak and Najafabad, local study |
Healthy adults |
Multistage random sampling |
2001 |
2012 |
≥ 35 |
T: 50.7 ± 11.6; M: 51.1 ± 11.9; F: 50.3 ± 11.3 |
Both |
Both |
T: 6,323; M: 3,068; F: 3,255 |
Modified ATP III |
|
T: 37.1 (35.9 - 38.3); M: 21.5 (20.0 - 23.0); F: 51.7 (49.9 - 53.4) |
|
Zarkesh et al. (37)
|
Tehran, (TLGS, phase III), local study |
Healthy adults |
Random sampling |
2006 - 2008 |
2012 |
≥ 19 |
T: 46.1 ± 16.1 |
Both |
U |
T: 365; M: 134; F: 231 |
JIS |
Waist circumference cut-off point was > 89 cm in men and > 91 cm in women |
T: 43.8 (38.6 -49) |
|
Ghorbani et al. (38)
|
Semnan, local study |
Healthy adults |
Multistage random sampling |
1384 |
2012 |
30 - 70 |
T: 45.7 ± 10.06; M: 46.6 ± 10.4; F: 45.1 ± 9.8 |
Both |
Both |
T: 3,799; M: 1,695; F: 2,104 |
Modified ATP III; IDF |
|
T: 28.5 (27.1 - 29.9); M: 17 (15.2 - 18.8); F: 37.8 (35.7 - 39.8). T: 35.8 (34.3-37.3); M: 25.4 (23.3-27.5); F: 44.1 (41.9-46.2) |
|
Rezaianzadeh et al. (39)
|
Yazd (phase I of Yazd Healthy Heart Program) |
Healthy adults |
Cluster sampling |
2004 - 2005 |
2012 |
20 - 74 |
T: 48.75 ± 15; M: 48.8 ± 15; F: 48.6 ± 15 |
Both |
U |
T: 2,000 |
IDF |
|
T: 30.16 (0.02); M: 31.6 (0.02); F: 30.2 (0.02) |
|
Hosseinpanah et al. (40)
|
Ghazvin, Kermanshah, Golestan, and Hormozgan (Iranian PCOS Prevalence Study), multicity study |
Females |
Stratified, multistage cluster sampling |
2009 - 2010 |
2011 |
18 - 45 |
T: 36 ± 7.5 |
F |
U |
T: 423 |
JIS |
Waist circumference cut-off point was ≥ 91 cm |
T: 18.3 (15.1 - 21.5) |
|
Esteghamati et al. (27)
|
Tehran, (the Third National Surveillance of Risk Factors of Non-communicable Diseases), local study |
Individuals with body mass index < 18.5 kg/m2 were excluded |
Random Cluster sampling |
2007 |
2011 |
25 - 64 |
T: 43.18 ± 0.3; M:43.4 ± 0.3; F: 43.0 ± 0.3 |
Both |
U |
T: 2,660; M: 1,245; F: 1,415 |
Modified ATP III; Iranian modified IDF (waist circumference cut-off point was ≥ 90 cm for both men and women) |
Individuals with self-reported diabetes were excluded |
T: 38.09 (36.23 - 39.9); M: 29.9 (27.3 - 32.5); F: 45.3 (42.6 - 47.9). T: 38.4 (36.5-40.2); M: 39.1 (36.3-41.8); F: 37.8 (35.2-40.3) |
|
Sahebari et al. (41)
|
Great Khorasan province, local study |
Healthy adults |
|
|
2011 |
|
T: 45.6 ± 12; M: 44.7 ± 12; F: 44.1 ± 13 |
Both |
Both |
T: 500; M: 69; F: 431 |
ATP III; IDF |
|
T: 53.8 (49.3 - 58.2); M: 21.7 (12.7 - 33.3); F: 51 (46.2 - 55.8). T: 34.2 (30 - 38.5); M: 29 (18.6 - 41.1); F: 57.8 (52.9 - 62.4) |
|
Esmaillzadeh et al. (42)
|
Tehran, local study |
Female teachers |
Multistage random cluster sampling |
2007 |
2011 |
40 - 60 |
T: 49 ± 6 |
F |
U |
T: 486 |
ATP III |
Subjects taking antihypertensive, lipid lowering, or antidiabetic medications were excluded |
T: 30 (25.9 - 34.3) |
|
Esteghamati et al. (43)
|
All 30 provinces of Iran (the Third National Surveillance of Risk Factors of Non-Communicable Diseases ) (SuRFNCD), national study |
Healthy adults |
Random cluster sampling |
2007 |
2011 |
25 - 64 |
T: 43.59 ± 11.2; M: 43.69±11.6; F: 43.5 ± 10.9 |
Both |
Both |
T: 3,045; M: 1,468; F: 1,577 |
IDF |
Waist circumference cut-off point was ≥ 90 cm in both males and females |
T: 39.9 (38.1 - 41.6); M: 38.2 (35.7 - 40.7); F: 41.5 (39 - 43.9) |
|
Ramezani et al. (44)
|
Ghazvin, Kermanshah, Golestan, and Hormozgan, multicity study |
Healthy adults |
Multistage random cluster sampling |
|
2011 |
18 - 45 |
|
F |
U |
T: 914 |
Modified ATP III |
|
T: 17.5 (15.09 - 20.1) |
|
Ghasemi et al. (45)
|
Tehran, (TLGS, phase 3), local study |
Healthy adults |
Multistage, stratified random cluster sampling |
2007 - 2008 |
2010 |
60 - 90 |
|
Both |
U |
T: 137; M: 89; F: 48 |
ATP III |
|
T: 43.8 (35.3 - 52.5); M: 30.3 (21.03 - 40.99); F: 68.8 (53.6 - 61.3) |
|
Delavari et al. (14)
|
All 30 provinces in Iran, national study |
Healthy adults |
Multistage Random cluster sampling |
2007 |
2009 |
25 - 64 |
T: 41.3 ± 3.81; M: 41.5 ± 2.64; F: 41.2 ± 2.74 |
Both |
Both |
T: 2,966 M: 1,431; F: 1,535 |
ATP III; Modified ATP III |
|
T: 35.6 (34.1 - 37.1); M: 28.8 (27.0-30.5); F: 42.8 (40.4 - 45.1). T: 42.3 (40.7-43.8); M: 36.3 (34.4-38.1); F: 48.5 (46.2-50.9) |
|
Jalali et al. (46)
|
Akbar abad Koar Fars near Shiraz, local study |
Healthy adults |
Simple random sampling |
2008 |
2009 |
18 - 90 |
T: 38.7 ± 14.3; M: 40.5 ± 15.9; F: 37.4 ± 13.7 |
Both |
R |
T: 1,402; M: 360; F: 1,042 |
ATP III; Modified ATP III; IDF |
|
T: 25.6 (23.3 - 27.9); M: 29.16 (24.5 - 34.1); F: 24.28 (21.7 - 27.0). T: 29 (26.5 - 31.4). T: 33 (30.4 - 35.4) |
|
Delavar et al. (47)
|
Babol, local study |
Female adults |
Systematic random sampling |
|
2009 |
30 - 50 |
F: 40.2 ± 0.2 |
F |
U |
T: 944 |
ATP III |
|
T: 31 (28.1-33.9) |
|
Sharifi et al. (48)
|
Zanjan, local study |
Healthy adults |
Stratified, multistage random sampling |
2002 - 2003 |
2009 |
> 20 |
|
Both |
U |
T: 2,941; M: 1,396; F: 1,545 |
Modified ATP III |
|
T: 23.7 (22.1 - 25.2); M: 23.1 (20.8 - 25.2); F: 24.4 (22.2 - 26.5) |
|
Sarrafzadegan et al. (49)
|
Isfehan, Irak, and Najaf-Abad, local study |
Healthy adults |
Two-stage random cluster sampling |
2000 - 2001 |
2008 |
≥ 19 |
|
Both |
Both |
T: 12,514; M: 6,123; F: 6,391 |
ATP III |
|
T: 23.3 (22.5 - 24.0); M: 10.7 (9.9 - 11.4) F: 35.1 (33.9 - 36.2) |
|
Hadaegh et al. (50)
|
Tehran, (TLGS, phase 1), local study |
Healthy adults |
Multistage random cluster sampling |
1999 - 2001 |
2008 |
≥ 20 |
T: 42.6 ± 13.6 |
Both |
U |
T: 4,568; M: 1,882; F: 2,686 |
WHO |
Diabetes patients were excluded |
T: 9.2 (8.3 - 10.0) |
|
Zabetian et al. (51)
|
Tehran, (TLGS, phase 1), local study |
Healthy adults |
Multistage random cluster sampling |
1999 - 2001 |
2007 |
≥ 20 |
T: 42.7 ± 15.0 ; M: 44.1 ± 15.6; F: 41.7 ± 14.4 |
Both |
U |
T: 10,368 M: 4,397; F: 5,971 |
IDF |
|
T: 31 (30.1 - 31.8); M: 21 (19.7 - 22.2); F: 41 ; (39.7 - 42.2) |
|
Nabipour et al. (52)
|
Bushehr, Genaveh, and Deilam, local study |
Healthy adults |
Random Cluster sampling |
2003 - 2004 |
2007 |
≥ 25 |
|
Both |
Both |
T: 3,723; M: 1,746; F: 1,977 |
ATP III |
|
T: 52.1 (47.3 - 50.6); M: 54.6 (50.3 - 53.6); F: 49.9 (44.5 - 48.5) |
|
Sadrbafghi et al. (53)
|
Yazd, local study |
Healthy adults |
Random Cluster sampling |
2004 |
2006 |
20 - 74 |
T:49 ± 18; M: 48.9 ± 15.4; F: 49.2 ± 21.4 |
Both |
U |
T: 1,110; M: 550; F: 557 |
ATP III |
|
T: 32.1 (29.3 - 34.9); M: 37.8 (33.7 - 42.0); F: 62.2 (57.9 - 66.1) |
|
Fakhrzadeh et al. (54)
|
Tehran, local study |
Healthy adults |
Single-stage cluster sampling |
2003 |
2006 |
25 - 64 |
T: 41.26 ± 12.06 |
Both |
U |
T: 1,480; M: 571; F: 909 |
ATP III |
|
T: 29.9 (27.6 - 32.2); M: 20.3 (17.08 - 23.85); F: 35.9 (32.74 - 39.07) |
|
Azizi et al. (16)
|
Tehran, (TLGS, phase 1), local study |
Healthy adults |
Multistage, stratified random cluster sampling |
1999 - 2001 |
2003 |
≥ 20 |
|
Both |
U |
T: 10,368; M: 4,397; F: 5,971 |
ATP III |
|
T: 33.7 (32.8 - 34.6); M: 24 (22.7 - 25.2); F: 42 (40.7 - 43.2) |
